Sedona
Sedona
The red rock country of Arizona. Where ancient stone rises from the desert floor and the light changes color with the hour, grounding everything it touches.
Less stress. Quieter mind. Better sleep.
Two clinically studied psychobiotics. One jar.
Rich and creamy. A clean, mild flavor. Our everyday classic.
Richer, with a deeper and more complex flavor. For those who want more from every jar.
Our richest and thickest. Cold-strained for maximum culture concentration.
Produced in a home kitchen under the Wyoming Food Freedom Act — not inspected by the state or a local health department. For informed consumers only.
*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Two cultures. Two pathways. One documented effect on the human mind.
Named for Helvetia (Switzerland). Isolated from Alpine cheese fermentation.
Among the first bacteria to colonize the infant gut. True human symbiont.
Sedona carries two cultures that were not chosen because they both support mood. They were chosen because they support mood through entirely different neurochemical pathways — and research shows those pathways work better in combination than either does alone.
The term "psychobiotic" was coined in 2013 by researchers Ted Dinan and John Cryan at University College Cork — defined as a live organism that, when ingested in adequate amounts, produces a measurable benefit for mental health through the gut-brain axis. It was a term that acknowledged something the research had been accumulating evidence for across multiple independent labs: specific gut organisms affect specific neurochemical systems. Not vaguely. Specifically.
L. helveticus R0052 was originally isolated from Alpine dairy fermentation — specifically the aged hard cheeses of Switzerland, where it has been used for centuries. Its distinguishing characteristic is not a single mechanism but a suite of them: it is one of the most proteolytic Lactobacillus species known, able to break down milk proteins into a range of bioactive peptides that have measurable effects on the central nervous system.
B. longum R0175 is a genuine human symbiont. It is among the first bacteria to colonize the infant gut after birth, present across human populations worldwide, and carries specific genetic adaptations — including an unusually large genome relative to its genus — that suggest a long co-evolutionary relationship with the human host. Among its documented capabilities: it carries the GAD gene, encoding glutamic acid decarboxylase, which converts glutamate to GABA — the brain's primary inhibitory neurotransmitter.
"This specific pairing — L. helveticus R0052 and B. longum R0175 — is not a formulation decision. It is the most clinically tested psychobiotic combination in the literature, with human RCT evidence going back to 2011 showing measurable reductions in anxiety, cortisol, and anger-hostility in healthy adults."
Two organisms depleted by the same modern conditions.
L. helveticus and B. longum are depleted by different mechanisms — but the conditions that deplete both are consistent with modern Western life: reduced fermented food consumption, antibiotic use, aging, and chronic psychological stress. The irony is not lost: the conditions that deplete the organisms that help regulate stress are themselves stress-related.
L. helveticus is not a natural gut colonizer — it must be continuously introduced through diet. Traditional Alpine communities consuming aged hard cheeses daily maintained consistent L. helveticus intake throughout life. Modern diets, dominated by pasteurized commercial dairy and processed food, provide no meaningful source. L. helveticus must come from deliberate fermented food consumption — or from a product like Sedona that ferments milk with it specifically.
Bifidobacterium populations — including B. longum — decline measurably and predictably with age. Infants have gut microbiomes dominated by Bifidobacterium. By middle age, Bifidobacterium may represent only a small fraction of the microbiome. By old age, they may be nearly undetectable in some individuals. This decline is among the most consistently replicated findings in the microbiome aging literature and is associated with reduced immune function and increased systemic inflammation.
Both L. helveticus and B. longum are sensitive to broad-spectrum antibiotics. B. longum populations are particularly affected: they are strict anaerobes that establish slowly and require specific conditions to recover after disruption. A course of antibiotics without deliberate Bifidobacterium replenishment can reduce B. longum populations to near-undetectable levels, with slow and incomplete recovery over subsequent months.
Chronic psychological stress reduces Bifidobacterium populations through cortisol's direct effects on gut motility and microbial composition. This creates a feedback loop: stress depletes B. longum, reduced B. longum reduces GABA signaling and HPA axis regulation, reduced GABA increases stress sensitivity, increased stress further depletes B. longum. Sedona addresses the biological side of this loop — it cannot address the stress itself, but it can interrupt the feedback where the biology allows.
Two pathways to the same outcome.
Each culture operates through a distinct neurochemical pathway. Together, they address the gut-brain connection from two directions simultaneously. Here is each, separately and precisely.
Produces casozepine and related bioactive peptides from milk protein hydrolysis. Increases tryptophan availability for serotonin synthesis. Directly supports the serotonergic pathway from the gut upward.
Carries the glutamic acid decarboxylase gene. Converts glutamate to GABA in the gut. GABA activates vagal afferent receptors. Signal travels to brainstem and cortex. Cortisol response is modulated.
L. helveticus — Bioactive Peptides & Serotonin
L. helveticus is among the most proteolytic Lactobacillus species — it produces multiple cell-wall-bound and secreted proteinases and peptidases that hydrolyze milk proteins (primarily caseins) into short peptide fragments. Some of these fragments have direct biological activity in the central nervous system. Most notably, casozepine — derived from alpha-s1-casein — has documented affinity for GABA-A receptors, the same receptors targeted by benzodiazepine medications, producing anxiolytic effects at much lower intensity through a natural food-derived mechanism.
L. helveticus fermentation increases the bioavailability of tryptophan — the dietary amino acid precursor to serotonin. Over 90 percent of the body's serotonin is synthesized in the gut. The enteroendocrine cells that produce serotonin require adequate tryptophan availability. L. helveticus's effect on tryptophan metabolism — both through competitive binding reduction with other gut bacteria that consume tryptophan for their own pathways, and through protein hydrolysis that releases free tryptophan — supports the gut's serotonin-producing capacity.
Several of the bioactive peptides produced by L. helveticus fermentation are small enough to pass through the blood-brain barrier — the selective membrane that prevents most blood-borne molecules from entering the brain. Casozepine, in particular, has been shown to reach the central nervous system following oral ingestion. Once there, it can directly interact with GABA-A receptors in brain tissue — representing a direct gut-to-brain chemical pathway rather than a signaling-mediated one.
B. longum — GABA Production & HPA Axis Regulation
B. longum carries the gene encoding glutamic acid decarboxylase (GAD) — the enzyme that catalyzes the conversion of glutamate to gamma-aminobutyric acid (GABA). GABA is the brain's primary inhibitory neurotransmitter. It reduces neural excitability throughout the nervous system, facilitates sleep onset, reduces anxiety, and counterbalances excitatory glutamate signaling. The GAD gene is present in all confirmed B. longum cultures and is constitutively expressed — meaning B. longum actively produces GABA as a metabolic byproduct throughout its existence in the gut.
Vagal afferent neurons embedded in the gut wall express GABA receptors. When B. longum produces GABA in the intestinal environment, a portion activates these vagal receptors directly — generating ascending signals that travel from the gut through the brainstem to the cortex. The critical evidence: in animal models where the vagal nerve has been severed, the anxiolytic effects of B. longum supplementation disappear entirely. The vagal pathway is not incidental — it is the primary route by which gut-derived GABA influences brain function.
The hypothalamic-pituitary-adrenal (HPA) axis is the body's primary stress response system. Activation produces cortisol — useful for acute stress, damaging when chronically elevated. B. longum modulates HPA axis sensitivity through vagal signaling pathways that dampen the magnitude of cortisol release in response to stressors. The Messaoudi 2011 trial measured urinary free cortisol — the most reliable index of HPA activation — and found significantly lower levels in the probiotic group. Reduced cortisol is not reduced awareness; it is proportionate response.
L. helveticus addresses the serotonergic system from the gut through bioactive peptides and tryptophan availability. B. longum addresses the GABAergic system and the HPA axis through direct GABA production and vagal signaling. These are distinct neurotransmitter systems with different regulatory functions. The Messaoudi trial tested the combination — not either culture alone — and the breadth of outcomes (anxiety, depression, anger-hostility, cortisol, problem-solving ability) is consistent with two complementary pathways operating simultaneously rather than one culture producing all effects.
Acadia (L. reuteri) operates through the oxytocin-vagus nerve pathway — affecting social connection, wound healing, sleep quality, and gut barrier integrity. Sedona operates through GABA production, serotonin precursor support, and HPA axis modulation — affecting stress reactivity, anxiety, mood baseline, and cortisol. They address overlapping emotional territory through entirely different mechanisms. People who use both as part of a rotation address the gut-brain connection from three different neurochemical directions simultaneously.
Published research. Read it yourself.
The Messaoudi 2011 trial remains the most cited human RCT for psychobiotic interventions. Four studies establishing the evidence base for this specific combination.
Read the detail
A randomized, double-blind, placebo-controlled trial in 55 healthy adult volunteers — not clinical patients, but healthy people with normal baseline psychological function. Participants received the L. helveticus R0052 + B. longum R0175 combination or placebo for 30 days. Outcomes included validated psychological measures (Hopkins Symptom Checklist for anxiety and depression, Hospital Anxiety and Depression scale), anger-hostility scores, problem-solving ability, and both serum and urinary free cortisol.
The probiotic group showed significantly lower scores on anxiety, depression, and anger-hostility measures compared to placebo. Urinary free cortisol — the most reliable index of HPA axis activation — was significantly lower in the probiotic group. Problem-solving scores improved. The findings were in healthy volunteers, making them particularly notable: the effect does not require clinical anxiety or depression as a baseline. The research established this combination as the most clinically validated psychobiotic pairing in the literature.
Read the detail
A mechanistic study designed to identify the pathway by which B. longum supplementation produces its documented anxiolytic effects. Researchers used a vagotomy model — surgically severing the vagal nerve in one group of animals — to test whether the vagal nerve was necessary for B. longum's behavioral effects, or whether the effects could occur through alternative pathways (bloodstream, immune signaling, etc.).
In animals with intact vagal nerves, B. longum supplementation produced the expected reductions in anxiety behavior. In animals whose vagal nerve had been severed, B. longum's anxiolytic effects were completely abolished — demonstrating that the vagal nerve is not merely one possible pathway but the necessary pathway. The study provided definitive mechanistic confirmation for what the human RCTs had documented: B. longum's effects on mood and anxiety operate through the gut-vagus-brain axis.
Read the detail
A systematic survey of GABA-producing capacity across human gut bacteria, identifying which genera and species carry the GAD gene (glutamic acid decarboxylase) and quantifying GABA production in fermentation conditions. The study specifically examined Lactobacillus and Bifidobacterium species, including B. longum, to characterize the scope and magnitude of gut-derived GABA production.
B. longum was among the highest GABA-producing organisms identified, with measurable GABA production in fermentation conditions comparable to dedicated GABA-producing fermentation organisms. The study documented that gut bacteria — particularly B. longum — produce GABA at quantities sufficient to activate intestinal GABA receptors and vagal afferent pathways, providing quantitative support for the mechanistic claim that gut-derived B. longum GABA production is a relevant neurochemical pathway rather than a marginal effect.
Read the detail
A mechanistic study characterizing casozepine — a decapeptide derived from alpha-s1-casein hydrolysis — and its interaction with GABA-A receptors. The research examined whether casozepine produces measurable anxiolytic effects, the molecular basis of those effects, and whether the mechanism was consistent with GABA-A receptor binding (the same receptors targeted by benzodiazepine anxiolytics).
Casozepine demonstrated measurable affinity for GABA-A benzodiazepine receptors and produced dose-dependent anxiolytic effects in behavioral tests — effects that were blocked by benzodiazepine receptor antagonists, confirming the mechanism. The study provided the molecular explanation for L. helveticus's contribution to Sedona's documented effects: milk protein hydrolysis during fermentation generates bioactive peptides that directly interact with the same receptor system targeted by prescription anxiolytic medications, at a natural food-derived potency level.
Note: PubMed links use search queries rather than direct DOIs. Identify the correct paper by author, journal, and year. All studies described are published peer-reviewed research. Vital Yogurts is not affiliated with any research institutions cited.
Honest about what to expect.
Sedona's effects are not immediate. Neurochemical shifts through the gut-brain axis build over weeks, not days. The Messaoudi trial ran 30 days — and that is the appropriate timeframe to evaluate.
-
1
A quieter relationship with stress — proportionate, not absent
The most commonly described effect of consistent Sedona use is not the absence of stress response — it is the sense that the same stressors feel proportionate rather than overwhelming. GABA modulation of the HPA axis does not remove the cortisol response to genuine threats; it recalibrates the threshold. People describe the same situations feeling manageable rather than escalating. This typically becomes noticeable between weeks two and four of consistent daily use.
-
2
Improved mood baseline — not elevation, stability
The Messaoudi trial measured reductions in depression and anger-hostility scores alongside anxiety. What people typically describe is not a mood lift but a steadier baseline — fewer unprovoked dips, less irritability at minor frustrations, a sense of returning to equilibrium faster after emotional disruption. This is the serotonin precursor pathway working over weeks of consistent fermented culture consumption, not a pharmacological effect.
-
3
Better sleep onset
GABA is the primary neurotransmitter that facilitates sleep onset — it is the signal that tells an activated nervous system to quiet down. Reduced cortisol in the evening hours (a documented effect of B. longum's HPA axis modulation) and elevated GABAergic tone combine to make the transition from alertness to sleep easier. This is not sedation. It is the nervous system finding its resting state more reliably rather than remaining activated past its useful range.
-
4
Easier cognitive engagement under pressure
The Messaoudi trial included a problem-solving outcome — and found improvement in the probiotic group. This is consistent with what reduced cortisol and improved GABAergic tone produce: a nervous system that is less in reactive mode and more able to sustain focused attention. People who use Sedona over extended periods often describe improved ability to think clearly during high-pressure situations — not more intelligence, but less cortisol-driven cognitive interference.
Our Live Fermented Milks are genuinely potent — in a way you won't find in store-bought products. When you introduce a large number of live beneficial cultures into a microbiome that has grown quieter over time, your body notices. Some people feel temporary bloating or mild discomfort in the first hour or two after their first few servings. This is your body adjusting. It passes. Start with two to four ounces and pay attention to how you feel before adding more. The daily ritual builds over weeks, not hours.
Cultures that complement Sedona.
Sedona addresses the gut-brain axis through GABA and serotonin. Acadia addresses it through oxytocin. Together they cover three distinct neurochemical pathways from the same foundation.
The oxytocin-vagus nerve culture. Complementary gut-brain pathway to Sedona — different neurotransmitter, different primary effects.
Cascade Bacillus subtilisVitamin K2 production and foundational gut resilience. The hardiest culture in the line — the one worth maintaining indefinitely.
Shenandoah Bifidobacterium infantisGentle foundational gut support through butyrate production and immune education. A natural long-term companion to Sedona.